Plant Comparison
Hawthorn vs Pygeum
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Hawthorn and Pygeum: both belong to the Rosaceae family; they share 3 indicated uses (arthritis / joint pain, inflammation (general), skin irritation); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Hawthorn | Pygeum | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 5/10 | Stronger for Pygeum |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 5/10 | Stronger for Pygeum |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Principal cardioprotective and antioxidant polyphenols characterised by chemical profiling of leaf, flower and fruit.
Contribute to the vasoactive and antioxidant effects, the basis for extract standardisation.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain
inferred from anti-inflammatory action
Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain
Supports lower urinary tract symptoms of benign prostatic hyperplasia (BPH) - a Cochrane meta-analysis of 18 RCTs (1562 men) found a moderate improvement in urinary symptoms and flow versus placebo, but the trials were small, short and methodologically weak, so the evidence remains uncertain
Safety, Cautions & Contraindications
Generally well tolerated. Hawthorn should not replace prescribed cardiac medications without medical supervision. May potentiate the effects of cardiac glycosides (digoxin), antihypertensive drugs, and coronary dilators. Not recommended during pregnancy and breastfeeding due to insufficient safety data. Mild side effects (nausea, dizziness, GI upset) occasionally reported.
Duke (2002) rates hawthorn as +++ — one of the most clinically supported cardiovascular herbs. Clinical evidence (score 2) supports its use for decreasing cardiac output (NYHA functional Stage II heart failure), as recognized by Commission E. Key activities include vasodilation, positive inotropic effects, and antioxidant protection of vascular tissue. Dose: 160–900 mg standardized leaf/flower extract (containing 18.75% oligomeric proanthocyanidins) daily. Duke emphasizes that hawthorn should not replace conventional heart failure therapy, and therapeutic effects may take 4–8 weeks to emerge. Mild interactions with cardiac glycosides (digitalis) are possible (Duke, 2002).
Lower urinary tract / prostate symptoms must be medically assessed first to exclude prostate cancer. The evidence is mixed and rests on small, short, methodologically weak trials, so men with moderate or severe BPH should not rely on it instead of proven treatment.
Generally well tolerated, with mild gastrointestinal effects the most common report.
External Ids
Botanical Description
Small deciduous tree or large shrub, densely thorny, with deeply lobed, glossy leaves (more deeply cut than midland hawthorn). Clusters of small, five-petalled white flowers with a strong, musky scent appear in spring ('May blossom'), followed by small red berries (haws), each containing a single seed (nutlet) - the origin of the species name monogyna.[4]
Evergreen tree (Rosaceae), 10-30 m tall, with dark, fissured, red-brown bark (the source of the common name 'red stinkwood', from its unpleasant smell when cut). Leaves are glossy dark green, leathery, oblong with finely toothed margins. Small white, five-petalled flowers are borne in axillary racemes, followed by small reddish-brown, two-lobed fruit.
Habitat
One of the commonest hedgerow and scrub trees of Europe, growing in hedgerows, woodland edges, scrub and pasture on a wide range of soils; native to Europe, North Africa and Western Asia.[4]
Native to montane forests of central and southern Africa (and Madagascar), growing at moderate to high altitude (roughly 900-3400 m). The species is CITES-listed and conservation-threatened owing to over-harvesting of bark for the pharmaceutical trade.
Harvesting
Flowers are picked as they open in May, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn after the first frosts soften them slightly; all three parts are traditionally combined.[4]
Bark is traditionally stripped from mature trees. Unsustainable stripping - especially removing bark all the way round the trunk - kills the tree and has driven population decline, so sustainable, partial and rotational bark harvesting or cultivated sources are recommended.
Traditional Uses
Common hawthorn shares the same long cardiovascular and calming tradition as midland hawthorn, used across European herbal medicine as a heart tonic for mild circulatory complaints, palpitations and nervous tension, and remains one of the most clinically studied cardiovascular botanicals.[4]
Prunus africana bark has a traditional use in East and Central African ethnomedicine for urinary complaints, and its extract (marketed as Pygeum) became one of the most widely used European phytotherapy remedies for benign prostatic hyperplasia (BPH) symptoms in the 20th century. Clinical evidence for symptom benefit is moderate but drawn from small, methodologically weak trials.[11]
Preparations
Dosage
The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.
The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.
Clinical trials have most often used around 100-200 mg/day of standardised lipophilic bark extract, divided into two doses. Educational reference only, not a prescription; any prostate or urinary symptom should be medically assessed first.
References
Drug Class Interactions
Not documented
Lookalikes Review
References & Sources
- Ez-Zahra Amrati, F., Mssillou, I., Boukhira, S., Djiddi Bichara, M. et al (2024) 'Phenolic Composition of Crataegus monogyna Jacq. Extract and Its Anti-Inflammatory, Hepatoprotective, and Antileukemia Effects', Pharmaceuticals (Basel), 17(6), pp. 786. doi:10.3390/ph17060786 Preclinical
https://doi.org/10.3390/ph17060786 - Lis, M., Szczypka, M., Suszko-Pawłowska, A., Sokół-Łętowska, A. et al (2019) 'Hawthorn (Crataegus monogyna) Phenolic Extract Modulates Lymphocyte Subsets and Humoral Immune Response in Mice', Planta Medica, 86(2), pp. 160-168. doi:10.1055/a-1045-5437 Preclinical
https://doi.org/10.1055/a-1045-5437 - Paun, G., Neagu, E., Albu, C., Alecu, A. et al (2024) 'Antioxidant and Antidiabetic Activity of Crataegus monogyna L. and Cornus mas Fruit Extracts', Molecules, 29(15), pp. 3595. doi:10.3390/molecules29153595 Preclinical
https://doi.org/10.3390/molecules29153595 - Nabavi, S.F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M. and Sobarzo-Sanchez, E (2015) 'Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications', Nutrients, 7(9), pp. 7708-7728. doi:10.3390/nu7095361 Meta-analysis / review
https://doi.org/10.3390/nu7095361 - Belabdelli, F., Bekhti, N., Piras, A., Benhafsa, F.M., Ilham, M. and Adil, S (2021) 'Chemical composition, antioxidant and antibacterial activity of Crataegus monogyna leaves' extracts', Natural Product Research, 36(12), pp. 3234-3239. doi:10.1080/14786419.2021.1958215 Preclinical
https://doi.org/10.1080/14786419.2021.1958215 - Jalali, A.S., Hasanzadeh, S. and Malekinejad, H (2012) 'Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences', Acta Medica Iranica, 50(1), pp. 1-8. Preclinical
https://scholar.google.com/scholar?q=Crataegus%20monogyna%20aqueous%20extract%20ameliorates%20cyclophosphamide-induced%20toxicity%20in%20rat%20testis%3A%20stereological%20evidences - Martin-Garcia, B., Razola-Diaz, M.D.C., Gomez-Caravaca, A.M., Benitez, G. and Verardo, V (2021) 'Setup of an Ultrasonic-Assisted Extraction to Obtain High Phenolic Recovery in Crataegus monogyna Leaves', Molecules, 26(15), pp. 4536. doi:10.3390/molecules26154536 Preclinical
https://doi.org/10.3390/molecules26154536 - Arslan, R., Bektas, N., Bor, Z. and Sener, E (2014) 'Evaluation of the antithrombotic effects of Crataegus monogyna and Crataegus davisii in the carrageenan-induced tail thrombosis model', Pharmaceutical Biology, 53(2), pp. 275-279. doi:10.3109/13880209.2014.914957 Preclinical
https://doi.org/10.3109/13880209.2014.914957 - Edwards, J.E., Brown, P.N., Talent, N., Dickinson, T.A. and Shipley, P.R (2012) 'A review of the chemistry of the genus Crataegus', Phytochemistry, 79, pp. 5-26. doi:10.1016/j.phytochem.2012.04.006 Meta-analysis / review
https://doi.org/10.1016/j.phytochem.2012.04.006 - Jarzycka, A., Lewinska, A., Gancarz, R. and Wilk, K.A (2013) 'Assessment of extracts of Helichrysum arenarium, Crataegus monogyna, Sambucus nigra in photoprotective UVA and UVB; photostability in cosmetic emulsions', Journal of Photochemistry and Photobiology B: Biology, 128, pp. 50-57. doi:10.1016/j.jphotobiol.2013.07.029 Preclinical
https://doi.org/10.1016/j.jphotobiol.2013.07.029 - Lucconi, G., Chlapanidas, T., Martino, E., Gaggeri, R., Perteghella, S. and Rossi, D (2013) 'Formulation of microspheres containing Crataegus monogyna Jacq. extract with free radical scavenging activity', Pharmaceutical Development and Technology, 19(1), pp. 65-72. doi:10.3109/10837450.2012.752387 Preclinical
https://doi.org/10.3109/10837450.2012.752387 - Zorniak, M., Szydlo, B. and Krzeminski, T.F (2017) 'Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences', Journal of Physiology and Pharmacology, 68(4), pp. 521-526. Meta-analysis / review
https://scholar.google.com/scholar?q=Crataegus%20special%20extract%20WS%201442%3A%20up-to-date%20review%20of%20experimental%20and%20clinical%20experiences - European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
https://doi.org/10.1177/0091270003253417 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
- Thompson, R.Q., Katz, D. and Sheehan, B (2019) 'Chemical comparison of Prunus africana bark and pygeum products marketed for prostate health', Journal of Pharmaceutical and Biomedical Analysis, 163, pp. 162-169. doi:10.1016/j.jpba.2018.10.004 Preclinical
https://doi.org/10.1016/j.jpba.2018.10.004 - Dvorkin, L. and Song, K.Y (2002) 'Herbs for benign prostatic hyperplasia', The Annals of Pharmacotherapy, 36(9), pp. 1443-1452. doi:10.1345/aph.1A228 Meta-analysis / review
https://doi.org/10.1345/aph.1A228 - Keehn, A. and Lowe, F.C (2015) 'Complementary and alternative medications for benign prostatic hyperplasia', The Canadian Journal of Urology, 22(Suppl 1), pp. 18-23. Meta-analysis / review
https://scholar.google.com/scholar?q=Complementary%20and%20alternative%20medications%20for%20benign%20prostatic%20hyperplasia - Kim, T.H., Lim, H.J., Kim, M.S. and Lee, M.S (2012) 'Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews', Maturitas, 73(3), pp. 180-185. doi:10.1016/j.maturitas.2012.07.007 Meta-analysis / review
https://doi.org/10.1016/j.maturitas.2012.07.007 - Cambronero, J., Osca-Garcia, J.M., Merino-Salas, S., Miguel, J.M. and others (2022) 'Effectiveness of treatment with Pygeum africanum in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a cross-sectional study in the real-world clinical practice in Spain (The PROFIT Study)', Archivos Espanoles de Urologia, 75(3), pp. 219-227. Clinical study
https://scholar.google.com/scholar?q=Effectiveness%20of%20treatment%20with%20Pygeum%20africanum%20in%20patients%20with%20lower%20urinary%20tract%20symptoms%20and%20benign%20prostatic%20hyperplasia%3A%20a%20cross-sectional%20study%20in%20the%20real-world%20clinical%20practice%20in%20Spain%20%28The%20PROFIT%20Study%29 - Quiles, M.T., Arbos, M.A., Fraga, A., de Torres, I.M. and others (2010) 'Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)', The Prostate, 70(10), pp. 1044-1053. doi:10.1002/pros.21138 Preclinical
https://doi.org/10.1002/pros.21138 - Salinas-Casado, J., Esteban-Fuertes, M., Carballido-Rodriguez, J. and Cozar-Olmo, J.M (2020) 'Review of the experience and evidence of Pygeum africanum in urological practice', Actas Urologicas Espanolas, 44(1), pp. 9-13. doi:10.1016/j.acuro.2019.08.002 Meta-analysis / review
https://doi.org/10.1016/j.acuro.2019.08.002 - Villar, A., Silva-Fuentes, F., Mula, A. and Zangara, A (2024) 'Anti-Inflammatory Potential of Prunus africana Bark Extract: An In Vitro Study of Cytokine Release by Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells', International Journal of Molecular Sciences, 25(15), pp. 8298. doi:10.3390/ijms25158298 Preclinical
https://doi.org/10.3390/ijms25158298 - Larre, S., Camparo, P., Comperat, E., Boulbes, D. and others (2012) 'Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures', Asian Journal of Andrology, 14(3), pp. 499-504. doi:10.1038/aja.2011.132 Preclinical
https://doi.org/10.1038/aja.2011.132 - Rubegeta, E., Makolo, F., Kamatou, G., Enslin, G. and others (2023) 'The African cherry: A review of the botany, traditional uses, phytochemistry, and biological activities of Prunus africana (Hook.f.) Kalkman', Journal of Ethnopharmacology, 305, pp. 116004. doi:10.1016/j.jep.2022.116004 Meta-analysis / review
https://doi.org/10.1016/j.jep.2022.116004 - Keehn, A. and Lowe, F.C (2015) 'Complementary and alternative medications for benign prostatic hyperplasia', The Canadian Journal of Urology. Randomized trial
https://scholar.google.com/scholar?q=Complementary%20and%20alternative%20medications%20for%20benign%20prostatic%20hyperplasia - Dedhia, R.C. and McVary, K.T (2008) 'Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia', The Journal of Urology, 179(6), pp. 2119--2125. doi:10.1016/j.juro.2008.01.094 Meta-analysis / review
https://doi.org/10.1016/j.juro.2008.01.094 - Wilt, T. and Ishani, A. and Mac Donald, R. and Rutks, I. and Stark, G (2002) 'Pygeum africanum for benign prostatic hyperplasia', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001044 Meta-analysis / review
https://doi.org/10.1002/14651858.CD001044
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.